Advertisement

David Mauro named chief medical officer and VP of Advaxis Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DAVID MAURO was named as executive vice president and chief medical officer of Advaxis Inc.

Mauro will oversee the company’s clinical immuno-oncology programs. He most recently served as executive director and section head of Oncology Clinical Development at Merck & Co., where he was involved in oversight and implementation of multiple programs within the oncology portfolio, including its recently approved PD-1 inhibitor, Keytruda (pembrolizumab).

Prior to joining Merck, Mauro was director at Bristol-Myers Squibb, where his responsibilities included Erbitux (cetuximab) and Oncology Early Development.

During his career, Mauro has participated in multiple FDA submissions and approvals, including three successful new drug applications for Erbitux, Sprycel (dasatinib) and Sylatron (peginterferon alfa-2b), and two PMA filings for EGFR PharmDx and KRAS Companion Diagnostics.

Advertisement
Advertisement
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement